Nephros, Inc. (NEPH)
USD 1.81
(-2.16%)
USD 1.81
(-2.16%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.57 Million USD | 78.5% |
| 2022 | -7.32 Million USD | -75.85% |
| 2021 | -4.16 Million USD | 11.83% |
| 2020 | -4.72 Million USD | -48.6% |
| 2019 | -3.17 Million USD | 6.55% |
| 2018 | -3.4 Million USD | -320.52% |
| 2017 | -809 Thousand USD | 73.32% |
| 2016 | -3.03 Million USD | 1.81% |
| 2015 | -3.08 Million USD | 58.11% |
| 2014 | -7.37 Million USD | -99.32% |
| 2013 | -3.69 Million USD | -13.37% |
| 2012 | -3.26 Million USD | -38.22% |
| 2011 | -2.36 Million USD | -22.09% |
| 2010 | -1.93 Million USD | 4.59% |
| 2009 | -2.02 Million USD | 68.03% |
| 2008 | -6.33 Million USD | 75.96% |
| 2007 | -26.35 Million USD | -228.92% |
| 2006 | -8.01 Million USD | -46.54% |
| 2005 | -5.46 Million USD | 28.02% |
| 2004 | -7.59 Million USD | -34.78% |
| 2003 | -5.63 Million USD | -133.18% |
| 2002 | -2.41 Million USD | -122.73% |
| 2001 | -1.08 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -169 Thousand USD | 74.16% |
| 2024 Q2 | -289 Thousand USD | -71.01% |
| 2023 Q1 | -307 Thousand USD | 67.48% |
| 2023 FY | -1.57 Million USD | 78.5% |
| 2023 Q4 | -654 Thousand USD | -259.34% |
| 2023 Q3 | -182 Thousand USD | 57.97% |
| 2023 Q2 | -433 Thousand USD | -41.04% |
| 2022 Q2 | -1.13 Million USD | 44.42% |
| 2022 Q1 | -2.04 Million USD | -85.31% |
| 2022 FY | -7.32 Million USD | -75.85% |
| 2022 Q4 | -944 Thousand USD | 70.78% |
| 2022 Q3 | -3.23 Million USD | -184.42% |
| 2021 Q1 | -596 Thousand USD | 27.32% |
| 2021 Q2 | -1.18 Million USD | -98.99% |
| 2021 Q3 | -1.22 Million USD | -3.04% |
| 2021 Q4 | -1.1 Million USD | 9.74% |
| 2021 FY | -4.16 Million USD | 11.83% |
| 2020 Q3 | -1.07 Million USD | 37.57% |
| 2020 Q2 | -1.71 Million USD | -48.4% |
| 2020 FY | -4.72 Million USD | -48.6% |
| 2020 Q4 | -820 Thousand USD | 23.51% |
| 2020 Q1 | -1.15 Million USD | -464.39% |
| 2019 Q4 | -205 Thousand USD | 74.5% |
| 2019 Q3 | -804 Thousand USD | 19.84% |
| 2019 FY | -3.17 Million USD | 6.55% |
| 2019 Q2 | -1 Million USD | 28.76% |
| 2019 Q1 | -1.4 Million USD | -90.01% |
| 2018 Q1 | -1.42 Million USD | -210.86% |
| 2018 FY | -3.4 Million USD | -320.52% |
| 2018 Q4 | -741 Thousand USD | -34.73% |
| 2018 Q3 | -550 Thousand USD | 19.35% |
| 2018 Q2 | -682 Thousand USD | 52.27% |
| 2017 Q1 | -680 Thousand USD | -3.82% |
| 2017 FY | -809 Thousand USD | 73.32% |
| 2017 Q4 | 1.28 Million USD | 303.96% |
| 2017 Q3 | -632 Thousand USD | 19.59% |
| 2017 Q2 | -786 Thousand USD | -15.59% |
| 2016 Q3 | -706 Thousand USD | 15.45% |
| 2016 Q1 | -836 Thousand USD | 10.59% |
| 2016 Q2 | -835 Thousand USD | 0.12% |
| 2016 Q4 | -655 Thousand USD | 7.22% |
| 2016 FY | -3.03 Million USD | 1.81% |
| 2015 Q3 | -581 Thousand USD | 67.99% |
| 2015 Q2 | -1.81 Million USD | -846.91% |
| 2015 FY | -3.08 Million USD | 58.11% |
| 2015 Q4 | -935 Thousand USD | -60.93% |
| 2015 Q1 | 243 Thousand USD | 104.63% |
| 2014 Q4 | -5.25 Million USD | -643.77% |
| 2014 FY | -7.37 Million USD | -99.32% |
| 2014 Q3 | -706 Thousand USD | -7.95% |
| 2014 Q2 | -654 Thousand USD | 13.95% |
| 2014 Q1 | -760 Thousand USD | 35.32% |
| 2013 FY | -3.69 Million USD | -13.37% |
| 2013 Q3 | -611 Thousand USD | 8.94% |
| 2013 Q2 | -671 Thousand USD | 45.97% |
| 2013 Q4 | -1.17 Million USD | -92.31% |
| 2013 Q1 | -1.24 Million USD | -13.11% |
| 2012 Q1 | -557 Thousand USD | 12.7% |
| 2012 FY | -3.26 Million USD | -38.22% |
| 2012 Q3 | -853 Thousand USD | -13.13% |
| 2012 Q4 | -1.09 Million USD | -28.72% |
| 2012 Q2 | -754 Thousand USD | -35.37% |
| 2011 Q1 | -707 Thousand USD | -6.32% |
| 2011 Q2 | -602 Thousand USD | 14.85% |
| 2011 Q4 | -638 Thousand USD | -54.48% |
| 2011 Q3 | -413 Thousand USD | 31.4% |
| 2011 FY | -2.36 Million USD | -22.09% |
| 2010 Q1 | -528 Thousand USD | -9.32% |
| 2010 Q3 | -375 Thousand USD | -2.74% |
| 2010 Q4 | -665 Thousand USD | -77.33% |
| 2010 FY | -1.93 Million USD | 4.59% |
| 2010 Q2 | -365 Thousand USD | 30.87% |
| 2009 Q2 | -413 Thousand USD | 43.81% |
| 2009 FY | -2.02 Million USD | 68.03% |
| 2009 Q4 | -483 Thousand USD | -22.28% |
| 2009 Q1 | -735 Thousand USD | 18.96% |
| 2009 Q3 | -395 Thousand USD | 4.36% |
| 2008 Q4 | -907 Thousand USD | 32.62% |
| 2008 FY | -6.33 Million USD | 75.96% |
| 2008 Q1 | -1.64 Million USD | 92.44% |
| 2008 Q2 | -2.44 Million USD | -49.02% |
| 2008 Q3 | -1.34 Million USD | 44.93% |
| 2007 Q2 | -1.63 Million USD | -3.76% |
| 2007 Q4 | -21.69 Million USD | -1383.79% |
| 2007 Q3 | -1.46 Million USD | 10.31% |
| 2007 FY | -26.35 Million USD | -228.92% |
| 2007 Q1 | -1.57 Million USD | 30.32% |
| 2006 FY | -8.01 Million USD | -46.54% |
| 2006 Q3 | -1.9 Million USD | 12.62% |
| 2006 Q4 | -2.25 Million USD | -18.32% |
| 2006 Q1 | -2.04 Million USD | -58.1% |
| 2006 Q2 | -2.18 Million USD | -6.5% |
| 2005 Q3 | -1.74 Million USD | 14.0% |
| 2005 Q4 | -1.29 Million USD | 25.91% |
| 2005 Q1 | -392.88 Thousand USD | 80.52% |
| 2005 Q2 | -2.03 Million USD | -417.28% |
| 2005 FY | -5.46 Million USD | 28.02% |
| 2004 Q4 | -2.01 Million USD | -7.17% |
| 2004 Q2 | -1.84 Million USD | 0.0% |
| 2004 FY | -7.59 Million USD | -34.78% |
| 2004 Q3 | -1.88 Million USD | -1.78% |
| 2003 FY | -5.63 Million USD | -133.18% |
| 2002 FY | -2.41 Million USD | -122.73% |
| 2001 FY | -1.08 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -63.32 Million USD | 97.513% |
| AngioDynamics, Inc. | -184.34 Million USD | 99.146% |
| AtriCure, Inc. | -30.43 Million USD | 94.826% |
| Avinger, Inc. | -18.32 Million USD | 91.403% |
| Azenta, Inc. | -14.25 Million USD | 88.953% |
| BioLife Solutions, Inc. | -66.42 Million USD | 97.629% |
| The Cooper Companies, Inc. | 294.2 Million USD | 100.535% |
| Daxor Corporation | 280.64 Thousand USD | 661.217% |
| Ekso Bionics Holdings, Inc. | -15.19 Million USD | 89.637% |
| Femasys Inc. | -14.24 Million USD | 88.945% |
| GlucoTrack, Inc. | -7.09 Million USD | 77.808% |
| Harvard Bioscience, Inc. | -3.41 Million USD | 53.88% |
| Hologic, Inc. | 789.5 Million USD | 100.199% |
| ICU Medical, Inc. | -29.65 Million USD | 94.689% |
| Intuitive Surgical, Inc. | 1.79 Billion USD | 100.088% |
| KORU Medical Systems, Inc. | -13.74 Million USD | 88.538% |
| LeMaitre Vascular, Inc. | 30.1 Million USD | 105.232% |
| Innovative Eyewear, Inc. | -6.66 Million USD | 76.364% |
| Innovative Eyewear, Inc. | -6.66 Million USD | 76.364% |
| Masimo Corporation | 81.5 Million USD | 101.933% |
| Microbot Medical Inc. | -10.74 Million USD | 85.335% |
| Meihua International Medical Technologies Co., Ltd. | 11.62 Million USD | 113.548% |
| Merit Medical Systems, Inc. | 94.41 Million USD | 101.668% |
| NovoCure Limited | -207.04 Million USD | 99.239% |
| NEXGEL, Inc. | -3.15 Million USD | 50.111% |
| NEXGEL, Inc. | -3.15 Million USD | 50.111% |
| Singular Genomics Systems, Inc. | -94.82 Million USD | 98.339% |
| OraSure Technologies, Inc. | 53.65 Million USD | 102.935% |
| Pro-Dex, Inc. | 2.12 Million USD | 174.048% |
| Pulse Biosciences, Inc. | -42.21 Million USD | 96.269% |
| Predictive Oncology Inc. | -13.98 Million USD | 88.737% |
| Precision Optics Corporation, Inc. | -2.95 Million USD | 46.635% |
| QuidelOrtho Corporation | -10.1 Million USD | 84.406% |
| Repligen Corporation | 41.57 Million USD | 103.788% |
| Sanara MedTech Inc. | -4.3 Million USD | 63.399% |
| STAAR Surgical Company | 21.34 Million USD | 107.378% |
| Sharps Technology, Inc. | -9.84 Million USD | 83.997% |
| Utah Medical Products, Inc. | 16.63 Million USD | 109.468% |
| DENTSPLY SIRONA Inc. | -132 Million USD | 98.807% |
| Jin Medical International Ltd. | 2.87 Million USD | 154.721% |